A New Type of Perinuclear Anti-Neutrophil Cytoplasmic Antibody (p-ANCA) in Active Ulcerative Colitis but not in Crohn's Disease

Rump, J. A.; Schölmerich, Jürgen; Groß, Volker; Roth, Michael; Helfesrieder, Renate; Rautmann, A; Lüdemann, Jens; Gross, Wolfgang L.; Peter, Hans

doi:10.1016/s0171-2985(11)80509-7

Cited by 203 publications

(119 citation statements)

References 17 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…In PSC such antibodies were reported by Snook et al in 1989 [43] . These antibodies are also present in a large proportion of patients with AIH [44] and the name ANCA was applied due to the close resemblance to ANCAs found in several of the vasculitides [45,46] . ANCA is analyzed by incubating fixated human neutrophil slides with patient serum, and subsequently with secondary antibodies conjugated to a fluorophore.…”

Section: Antibodies Against Neutrophilsmentioning

confidence: 99%

Autoantibodies in primary sclerosing cholangitis

Hov¹,

Boberg²,

Karlsen³

2008

WJG

150

100

View full text Add to dashboard Cite

The aetiology of primary sclerosing cholangitis (PSC) is not known and controversy exists as to whether PSC should be denominated an autoimmune disease. A large number of autoantibodies have been detected in PSC patients, but the specificity of these antibodies is generally low, and the frequencies vary largely between different studies. The presence of autoantibodies in PSC may be the result of a nonspecific dysregulation of the immune system, but the literature in PSC points to the possible presence of specific antibody targets in the biliary epithelium and in neutrophil granulocytes. The present review aims to give an overview of the studies of autoantibodies in PSC, with a particular emphasis on the prevalence, clinical relevance and possible pathogenetic importance of each individual marker.

show abstract

Section: Antibodies Against Neutrophilsmentioning

confidence: 99%

Autoantibodies in primary sclerosing cholangitis

Hov¹,

Boberg²,

Karlsen³

2008

WJG

150

100

View full text Add to dashboard Cite

show abstract

“…In 1990, Rump, et al suggested the possible use of a new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active UC but not CD [21]. The utility of these antibodies in association with ASCA in diagnosing difficult cases of indeterminate colitis (IC) was illustrated by Joossens, et al when they determined that ASCA+/pANCA-status predicts CD in 80% of patients with IC while ASCA-/pANCA+ status predicts UC in 63.6% of patients with IC [22].…”

Section: Anti-neutrophil Cytoplasmic Antibodies (Ancas)mentioning

confidence: 99%

Bio-Markers of Inflammatory Bowel Disease: Past, Present, and Future

Bahgat¹

2017

Austin J Gastroenterol

View full text Add to dashboard Cite

Ulcerative colitis (UC) and Crohn's disease (CD) exemplify the two main arms of the spectrum of an idiopathic chronic disease known as inflammatory bowel disease (IBD). To date, this disease remained a puzzling dilemma in many aspects; including difficulties in its etiology/pathogenesis, diagnosis, severity assessment, treatment and outcomes/complications. Physicians usually get the diagnosis of IBD through a combination of clinical features, laboratory tests, radiology, as well as the invasive technique of endoscopy/biopsy. In spite of these efforts, the definite diagnosis can't be established in a significant cohort of cases. This paved the way to searching for laboratory biomarkers that are noninvasive, reproducible, rapid and relatively cheap than other modalities. Unfortunately, we're still far from these ideal biomarkers. Some biomarkers are already being used in daily practice including C-reactive protein (CRP) and fecal calprotectin while others are still in need for confirmation before being applied in clinical practice. In this review article, the authors are going to discuss the past, present, and future utility of biomarkers in IBD. This article aims at highlighting the uses and limitations of all possible current and novel biomarkers in every aspect of the disease from predisposition to prognosis.

show abstract

“…Loss of antigenic response after DNase digestion of neutrophils, however, seems to be a dominant characteristic of UC-specific pANCA and is termed DNase-sensitive pANCA [15].…”

Section: Serological Markers In Differentiating CD From Ucmentioning

confidence: 99%